Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss
Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial *

Abstract  Background: Early clinical trials have suggested that glutathione (GSH)offers protection from the toxic effects of cisplatin.

Patients and methods: One hundred fifty-one patients with ovariancancer (stage I–IV) were evaluated in a clinical trial of cisplatin(CDDP) ± glutathione (GSH). The objective was to determine whether GSHwould enhance the feasibility of giving six cycles of CDDP at 100mg/m2 without dose reduction due to toxicity.
Results: When considering the proportion of patients receiving six coursesof CDDP at any dose, GSH produced a significant advantage over control –58% versus 39%, (P = 0.04). For these patients there was asignificant difference between the reduction in creatinine clearance for GSHtreated patients compared with control – 74% versus 62%(P = 0.006). Quality of life scores demonstrated that for patients receivingGSH there was a statistically significant improvement in depression, emesis,peripheral neurotoxicity, hair loss, shortness of breath and difficultyconcentrating.
As an indication of overall activity, these patients werestatistically significantly more able to undertake housekeeping and shopping.Clinically assessed response to treatment demonstrated a trend towards abetter outcome in the GSH group (73% versus 62%) but this wasnot statistically significant (P = 0.25).
Conclusions: The results demonstrate that adding GSH to CDDP allows morecycles of CDDP treatment to be administered because less toxicity is observedand the patient's quality of life is improved.

* Legal Disclaimer: Chelation and Hyperbaric Therapy, Stem Cell Therapy, and other treatments and modalities mentioned or referred to in this web site are medical techniques that may or may not be considered “mainstream”. As with any medical treatment, results will vary among individuals, and there is no implication or guarantee that you will heal or achieve the same outcome as patients herein.

As with any procedure, there could be pain or other substantial risks involved. These concerns should be discussed with your health care provider prior to any treatment so that you have proper informed consent and understand that there are no guarantees to healing.

THE INFORMATION IN THIS WEBSITE IS OFFERED FOR GENERAL EDUCATIONAL PURPOSES ONLY AND DOES NOT IMPLY OR GIVE MEDICAL ADVICE. No Doctor/Patient relationship shall be deemed to have arisen simply by reading the information contained on these pages, and you should consult with your personal physician/care giver regarding your medical treatment before undergoing any sort of treatment or therapy.

Published on 04-17-2008